Eli Lilly and Company
Income Statement
| Line Item | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|
| Revenue | $21.84B | $20.37B | $18.63B | $15.69B |
| Zyprexa | $4.92B | $4.70B | $4.76B | $4.42B |
| Cialis | $1.56B | $1.44B | $1.19B | $971.0M |
| Alimta | $1.71B | $1.15B | $854.2M | $578.4M |
| Humalog | $1.96B | $1.73B | $1.47B | $1.30B |
| Humulin | $1.00B | $1.06B | $999.0M | $916.3M |
| Gemzar | $1.36B | $1.72B | $1.54B | $1.40B |
| Evista | $1.01B | $1.08B | $1.09B | $1.05B |
| Forteo | $843.0M | $778.6M | $709.1M | $599.8M |
| Strattera | $598.0M | $579.4M | $582.8M | $574.6M |
| Symbyax | $84.1M | $103.5M | $126.9M | $80.1M |
| Erbitux | $0 | $0 | $0 | $0 |
| Byetta | $390.8M | $420.2M | $334.8M | $155.1M |
| Trad jenta | $0 | $0 | $0 | $0 |
| Effient | $36.2M | $0 | $0 | $0 |
| Jardiance | $0 | $0 | $0 | $0 |
| Trulicity | $0 | $0 | $0 | $0 |
| Taltz | $0 | $0 | $0 | $0 |
| Olumiant | $0 | $0 | $0 | $0 |
| Verzenio | $0 | $0 | $0 | $0 |
| Emgality | $0 | $0 | $0 | $0 |
| Tyvyt | $0 | $0 | $0 | $0 |
| Cyramza | $0 | $0 | $0 | $0 |
| Baqsimi | $0 | $0 | $0 | $0 |
| Retevmo | $0 | $0 | $0 | $0 |
| Bebtelovimab | $0 | $0 | $0 | $0 |
| Mounjaro | $0 | $0 | $0 | $0 |
| Jaypirca | $0 | $0 | $0 | $0 |
| Zepbound | $0 | $0 | $0 | $0 |
| Omvoh | $0 | $0 | $0 | $0 |
| Ebglyss | $0 | $0 | $0 | $0 |
| Kisunla | $0 | $0 | $0 | $0 |
| Animal Health | $1.21B | $1.05B | $0 | $0 |
| Collaboration and Other Revenue | $0 | $0 | $0 | $0 |
| Other Pharmaceutical Products | $5.15B | $4.55B | $5.08B | $4.70B |
| Cost of Revenue | $4.25B | $4.38B | $4.25B | — |
| Gross Profit | $17.59B | $16.00B | $14.38B | — |
| Gross Margin | 80.6% | 78.5% | 77.2% | — |
| Operating Expenses | ||||
| Research & Development | $4.33B | $3.84B | $3.49B | — |
| SG&A Expense | $6.89B | $6.63B | $6.10B | — |
| Operating Income | $5.62B | $-1.54B | $3.88B | — |
| Operating Margin | 25.7% | -7.5% | 20.8% | — |
| Interest Expense | $261.3M | $-228.3M | — | — |
| Pretax Income | $5.36B | $-1.31B | $3.88B | — |
| Income Tax Expense | $1.03B | $764.3M | $923.8M | — |
| Net Income | $4.33B | $-2.07B | $2.95B | — |
| Net Margin | 19.8% | -10.2% | 15.8% | — |
| EPS (Basic) | $3.94 | $-1.89 | — | — |
| EPS (Diluted) | $3.94 | $-1.89 | — | — |
| Shares Outstanding (Basic) | 1.10B | 1.09B | — | — |
| Shares Outstanding (Diluted) | 1.10B | 1.09B | — | — |
| Dividends Per Share | $1.96 | $1.90 | — | — |